Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of REGN3918 in paroxysmal nocturnal hemoglobinuria
NL-OMON48439Phase 3Withdrawn
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pozelimab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence and severity of treatment-emergent adverse events and Proportion achieving LDH less than or equal to 1.5 times upper limit of normal through Week 26. Planned start Oct 2019; status: withdrawn.
02
Drugs
pozelimab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON48439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48439.